Axsome Therapeutics, Inc.
AXSM
$118.51
$1.371.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 72.13% | 61.95% | 66.04% | 81.27% | 86.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 72.13% | 61.95% | 66.04% | 81.27% | 86.65% |
| Cost of Revenue | 66.95% | 55.45% | 42.50% | 29.16% | 75.15% |
| Gross Profit | 72.66% | 62.55% | 68.74% | 87.91% | 87.91% |
| SG&A Expenses | 25.81% | 22.04% | 30.48% | 14.88% | 31.19% |
| Depreciation & Amortization | -0.06% | -1.07% | 0.00% | -0.06% | 0.06% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.51% | 23.14% | 42.50% | 25.73% | 54.25% |
| Operating Income | 40.94% | 19.24% | -11.92% | 25.79% | -28.61% |
| Income Before Tax | 38.33% | 13.08% | 24.40% | -2.74% | -17.05% |
| Income Tax Expenses | -- | -- | 126.15% | -- | -- |
| Earnings from Continuing Operations | 39.54% | 13.08% | 24.06% | -3.86% | -18.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.54% | 13.08% | 24.06% | -3.86% | -18.13% |
| EBIT | 40.94% | 19.24% | -11.92% | 25.79% | -28.61% |
| EBITDA | 42.39% | 20.22% | -11.69% | 27.06% | -28.92% |
| EPS Basic | 41.82% | 15.71% | 25.96% | -1.65% | -8.43% |
| Normalized Basic EPS | 41.84% | 19.52% | -11.62% | 25.17% | -14.77% |
| EPS Diluted | 41.82% | 15.41% | 25.96% | -1.65% | -8.43% |
| Normalized Diluted EPS | 41.84% | 19.52% | -11.62% | 25.17% | -14.77% |
| Average Basic Shares Outstanding | 3.93% | 3.12% | 2.56% | 2.17% | 8.94% |
| Average Diluted Shares Outstanding | 3.93% | 3.12% | 2.56% | 2.17% | 8.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |